Cognitive impairment is a core symptom domain of schizophrenia. The effect of
antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully …

Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease
and type II diabetes, are significant problems for patients receiving antipsychotic drugs and …

Mechanisms underlying antipsychotic cardiometabolic adverse effects are incompletely
understood. This hampers the identification of high-risk patients, low-risk antipsychotics and …

Objectives: To assess the methods and reporting of cardiometabolic outcome studies of the
first treated episode of psychosis, review key findings, and suggest directions for future …

Mental disorders are the greatest overall cause of disability. 1 Antipsychotic drugs (APDs)
are the most widely prescribed medications and are used frequently to control various …

Prescriptions for second-generation antipsychotics (SGAs) have surpassed those for first-
generation agents in the treatment of schizophrenia and bipolar disorder. While SGAs have …

Beside the therapeutic improvement over first-generation antipsychotics, the fact that
prescription of atypical agents is also associated to the emergence of severe metabolic …

OBJECTIVE: To explore the impact of premorbid and baseline body mass indices (BMIs) as
well as BMI of patient's parents and associated variables on the prediction of antipsychotic …

Background Weight gain is common for people with schizophrenia and this has serious
implications for a patient's health and well being. Switching strategies have been …

Second generation antipsychotics (SGAs) are widely prescribed to treat various disorders,
most notably schizophrenia and bipolar disorder; however, SGAs can cause abnormal …